Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016991 · ClinicalTrials.gov registry record · Phase 2
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00016991: Completed Phase 2 study, sponsored by Duke University.
NCT00016991 is a Phase 2 study that has completed, run by Duke University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00016991, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have glioblastoma multiforme in first relapse.
Interventions
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
What the finished NCT00016991 record still lists
NCT00016991 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which gefitinib is the first listed.
NCT00016991 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00016991 about?
NCT00016991 is a clinical study titled "ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse". RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have glioblastoma multiforme in first relapse.
What is the current status of trial NCT00016991?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-06. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00016991?
The interventions under investigation include: gefitinib (DRUG).
Who is sponsoring clinical trial NCT00016991?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia